Kornimate/medical-research-clean huggingface dataset:
the horsens aarhus femoroacetabular impingement syndrome training pilot study

Conditions: Femoroacetabular Impingement

Summary: the aim of the study is to investigate the feasibility of a training intervention in patients with femoroacetabular impingement syndrome (fais).

the aim of this study is to investigate the feasibility of a 12-weeks (progressive) exercise program in patients with fais. feasibility is evaluated on the recruitment strategy, patient adherence to the exercises and their experiences with and motivation for performing exercises. furthermore, the investigators wish to investigate the variation of data before and after the exercise program to help estimate a suitable sample size for a future randomized controlled trial.

Eligibility criteria:
inclusion criteria: 1. patients aged 18-50 years old 2. diagnosed with fais according to the warwick agreement 3. patients having cam morphology should have an alpha angle of \> 55 degrees on an anterior-posterior radiograph. 4. patients having pincer should have a lateral centre edge angle of \>39 degrees on an anterior-posterior radiograph. 5. lateral joint space width should be \>3 mm. 6. body mass index is below 30. 7. motivated for participation in a 12 week training program with 8 physical attendances. exclusion criteria: 1. received physiotherapist-led treatment in the past 3 months, 2. previous hip surgery in included hip or other major hip injury, 3. systemic conditions e.g. rheumatoid arthritis, cancer, 4. chronical pain syndromes, 5. unable to perform testing procedures, 6. unable to attend a 12-week treatment program or baseline and follow-up assessments 7. contraindications to radiographs (e.g. pregnancy) 8. unable to read or understand questionnaires and/or instructions
mechanism of action of transcranial magnetic stimulation

Conditions: Major Depressive Disorder; Depression

Summary: this is an observational neuroimaging study assessing the effects of tms on the brains of patients with unipolar depression.

this project aims to use functional connectivity magnetic resonance imaging (fcmri) to study patients with unipolar depression receiving tms. patients will be scanned before and after a full course of tms and clinical measures for depression severity and memory will be obtained at the same times.the project has the following aims and hypothesis: (1) to determine the therapeutic antidepressant mechanism of action of tms at the circuit level (2) to study the use of fcmri as a state biomarker for depression (3) to study the use of fcmri as a predictor of response for depression.

Eligibility criteria:
inclusion criteria: 1. males and females between the ages of 18-80 2. dsm-iv diagnosis of depressive episode 3. patients requiring tms treatment as part of their psychiatric care exclusion criteria: 1. comorbid dsm-iv primary diagnoses of schizoaffective disorder, schizophrenia or dementia. 2. substance use disorder (abuse or dependence) with active use within the last 3 months 3. severe or unstable medical illness. 4. mri contraindications as determined by mgh department of radiology.

Keywords: transcranial magnetic stimulation
a study of ibi311 in subjects with active thyroid eye disease

Conditions: Thyroid Eye Disease

Summary: this is a multicenter, randomized, double-masked, placebo-controlled phase ii/iii study in subjects with active thyroid eye disease. approximately 114 subjects meeting study eligibility criteria will be randomly assigned to ibi311 or placebo on day 1 (d1) in a 2:1 ratio stratified by smoking status


Eligibility criteria:
key inclusion criteria: 1. written informed consent. 2. male or female subject between the ages of 18 and 80 years, inclusive, at screening. 3. weight between 45 and 100 kg (inclusive). 4. clinical diagnosis of graves' disease associated with active ted with a cas ≥ 3 for at least one eye at screening and baseline. 5. moderate-severe active ted (not sight-threatening but has an appreciable impact on daily life), usually associated with at least two of the following: lid retraction ≥2 mm, moderate or severe soft tissue involvement, exophthalmos ≥ 3 mm above normal for race and gender, and/or inconstant or constant diplopia. 6. female subjects should be fertile women who are sterile or have a negative blood pregnancy test during the screening period and who agree to take contraceptive measures within 120 days from the screening period to the last medication; male subjects should agree to use contraception from the screening period to 120 days after the last dose. key exclusion criteria: subjects will be ineligible for study participation if they meet any of the following criteria: 1. at the time of screening, according to the subject's chief complaint or medical record, the time of first symptoms of active thyroid eye disease appeared in \> 270 days; 2. optimal corrected vision loss due to optic neuropathy, defined as two lines of vision loss due to optic neuropathy within the past 180 days, new visual field defects, or color vision impairment secondary to optic nerve involvement; 3. corneal ulcers with no relief after treatment were determined by the investigator; 4. baseline cas decreased by more than 2 points compared with screening; 5. at any time prior to baseline or during the study period planned to receive orbital radiation therapy or ted specific surgery, including orbital decompression, strabismus surgery, and eyelid retraction correction; 6. poor thyroid function control was defined as free triiodothyronine (ft3) or free tetriodothyronine (ft4) deviated more than 50% from the normal reference range of the local research center laboratory during screening;
does extra-fine hydrofluoroalkane-beclomethasone dipropionate (hfa-bdp) suppress small airways inflammation in chronic obstructive pulmonary disease (copd)?

Conditions: COPD

Summary: chronic obstructive pulmonary disease or 'copd' is a chronic disease, which means that it cannot be cured, but that inhalers and tablets can be used to control the symptoms. in copd, the airways become inflamed which can cause coughing and make the airways tighten. this 'inflammation' is the root of the problem in copd. the airways of the lung start in the windpipe and branch like the branches of a tree, getting smaller and smaller. in copd the inflammation is deep in the lungs, out to the very small airways. different inhalers make the medicines into different sized particles. most steroid inhalers used for copd make the medicine into particles which are too big to get into the very small airways ('coarse particles'). other inhalers make a mist, with much smaller particles ('fine particles'). these are as small as the smallest airways in the lungs. doctors have recently found a way to measure the inflammation in the small airways that are affected in copd. the investigators want to find out if taking one of these 'fine-particle' steroid inhalers can treat that inflammation.


Eligibility criteria:
inclusion criteria: * current or ex-smokers * \> 40 years of age with a greater than 15 pack year history of smoking * post-bronchodilator fev1/fvc ratio \< 0.7 * fev1 \< 80% predicted * cano \> 3 ppb at screening * informed consent and ability to perform exhaled nitric oxide assessment exclusion criteria: * oral steroid use or exacerbation within 6 weeks * greater than 2 exacerbations requiring treatment in the previous 6 months * requirement for domiciliary oxygen * pregnancy or lactation * known or suspected contra-indication to any of the imp's * diagnosis of asthma
genetic, neurophysiological and psychological predictive factors of chronic neuropathic pain after surgery for breast cancer

Conditions: Breast Cancer

Summary: the aim of the study is to establish the genetic, neurophysiological and psychological phenotype of the patients presenting a persistent neuropathic pain after surgery of the breast cancer, by comparing the neuropathic painful patients with the not painful and with the not neuropathic painful . this will be realized on a transverse cohort ("seintinelle"cohort) and confirmed on a forward-looking longitudinal cohort.


Eligibility criteria:
for both arms: inclusion criteria: * women over 18 years * having given a written consent form * affiliated to the social security scheme * french language (read, written and spoken) * accepting the principle of the study and able to respect the conditions of the study. exclusion criteria: * other cancer or aids in evolution * bilateral mastectomy * presence of chronic pain before the intervention for breast cancer, * occupational accident, dispute or search for compensation * previous surgery on the same territory * peripheral neurological pathology or central (brain damage, multiple sclerosis) susceptible to interfere with the evaluation of the post-operative pain * heavy psychiatric histories: psychosis, severe depression having motivated a hospitalization, a suicide attempt * current major depressive episode at the time of the evaluation (cf. criterion diagnosis of the diagnostic and statistical manual of mental disorders (dsm-5)) * abuse of drug or psychoactive substance (cf. definition of the dsm-5) during the last six months; cognitive disorders (mmse 24/30) or psychological incompatible with the respect and/or the understanding of the protocol * patients participating in another protocol of biomedical research. for longitudinal study: inclusion criteria: * patients who can be followed during the total duration of the study ( 12 months) for the longitudinal arm of the forward-looking study * patients that must be operated for one of the two types of surgery: preservative surgery or mastectomy for breast cancer with ganglionic cleaning out * chemotherapy or radiotherapy before the surgery exclusion criteria: * previous surgery for a breast cancer * patients that must be operated for a surgery of the breast without ganglionic cleaning out for transversal study: inclusion criteria: - patients operated for a conservative surgery or a mastectomy for breast cancer with ganglionic cleaning out during 2 years before the inclusion exclusion criteria * patients operated for a surgery of the breast without ganglionic cleaning out * patients operated for more than 2 years

Keywords: neuropathic pain
intravenous fluids after laparoscopic cholecystectomy

Conditions: Postoperative Nausea; Postoperative Vomiting; Renal Function Abnormal; Hunger; Thirst; Fluid Electrolyte Disorders

Summary: perioperative intravenous fluid (iv) administration has been the standard procedure since 1832 and, is a widely used practice sometimes under inadequate criteria. the present work aims at verifying the clinical need that justifies the common iv fluid prescription on the postoperative (po) period in patients undergoing videolaparoscopic cholecystectomy (cvl) elective.

patients undergoing elective laparoscopy cholecystectomies were randomized to either routine practice fluid prescription (control group) or no iv fluids in the postoperative period. thirst, hunger, presence of nausea and vomiting, renal function and personal satisfaction were assessed. body composition was evaluated by bioimpedance

Eligibility criteria:
inclusion criteria: elective laparoscopy cholescitectomy; no intraoperative complication - exclusion criteria: co-existing severe renal failure, cardiac failure or pulmonary disease -

Keywords: saline solution laparoscopy cholecystectomy outcomes
mental processes for rating pain intensity

Conditions: Pain

Summary: this new study builds on the principal investigator's earlier studies to improve communication about pain. the research team seeks to better understanding of the mental processes needed to rate pain.


Eligibility criteria:
general inclusion criteria: * 18 years old or older; * visited a hcp for treatment of a painful musculoskeletal condition within previous year; * has usually felt, at least, "mild" musculoskeletal pain on most days of the last 3 months in multiple locations; and * has felt variable musculoskeletal pain intensity during the last 3 months. general exclusion criteria: * past or current employment as a licensed healthcare provider; * diagnosed with a cardiac arrhythmia; * has a battery-powered implant in the neck, chest, abdomen, or spine (e.g., pacemaker); * diagnosed with a neurological condition that causes uncontrolled movement (e.g., parkinsonism, epilepsy, etc.); * smokes cigarettes or vapes; (6) has abused substances during the last week; or * allergic to skin adhesives.
a study to evaluate the quality of life of male and female adult patients with severe refractory atopic dermatitis treated with dupilumab in czech republic

Conditions: Atopic Dermatitis

Summary: assessment of the relationship between treatment response (easi75) and change in quality of life (eq-5d) by week 24. description of the: * change in disease activity after 16 and 24 weeks * change in subject and family quality of life after 16 and 24 weeks * change in sleep quality after 16 and 24 weeks * change in anxiety after 16 and 24 weeks * change in depression after 16 and 24 weeks * safety and tolerability

28 weeks

Eligibility criteria:
inclusion criteria: * patient eligible for dupixent therapy of ad according to the current spc and reimbursement criteria given by the sukl * signed informed consent * 18 years and older (study questionnaires are validated for this age group). patient is able to follow the prescribed regimen, routine follow-up visits and to fill the questionnaires exclusion criteria: - patient not eligible for dupixent therapy of ad according to the current spc and reimbursement criteria given by the sukl. the above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
breast cancer survivorship biorepository

Conditions: Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Invasive Breast Carcinoma

Summary: this study collects blood samples as well as clinical and self-report data from stage i-iii breast cancer survivors to create a biorepository for future use. the creation of this biorepository will allow for future research into links between individual, molecular, and genomic signatures and cancer outcomes.

primary objective: i. to create an annotated biorepository with prospectively collected blood samples from breast cancer survivors. secondary objectives: i. to collect comprehensive data on social determinants of health (e.g., race/ethnicity, acculturation, socioeconomic status, and access to care), environmental exposures (based on zip codes/geocoding), lifestyle (e.g., diet, tobacco use), clinicopathologic characteristics, treatment history, follow-up and current disease status, survivorship-related issues. ii. to establish an efficient process for researchers to utilize the biorepository for breast cancer and survivorship-related studies. outline: patients complete surveys, undergo collection of blood samples, and review of medical records on study.

Eligibility criteria:
inclusion criteria: * women of all racial and ethnic groups 18 years of age or older * women with a diagnosis of invasive breast cancer (stages i-iii) within the past 7 years * women who have completed active treatment for breast cancer (surgery, chemotherapy, her2-directed therapy and radiation) * prior participation on clinical trials is allowed exclusion criteria: * current receipt of interventional clinical trial participation * stage iv (metastatic) cancer * prior history of recurrence (except recurrence following ductal carcinoma in situ) * inability to give informed consent * unable to speak english, spanish, chinese, or korean
a study to assess deucravacitinib post-marketing surveillance in participants with psoriasis in japan

Conditions: Psoriasis

Summary: the purpose of this study is to determine the safety and effectiveness of deucravacitinib for the treatment of plaque psoriasis (pso) in japan participants.


Eligibility criteria:
inclusion criteria: * psoriasis (pso) participants who received deucravacitinib for the first time of the approved indications at medical institutions in japan will be enrolled in this pms exclusion criteria: * participants receiving deucravacitinib for an off-label indication will be excluded from this pms.

Keywords: psoriasis deucravacitinib
message from local pharmacy team

Conditions: COVID-19

Summary: this experiment is part of a megastudy with a total of ten experimental conditions and a holdout control condition to which patients will be randomly assigned. the focal comparison in this experiment is between a message encouraging vaccination that comes from a patient's local pharmacy team and a control message telling patients that an updated covid booster vaccine is waiting for them. the intervention testing if text messages encouraging vaccination that come from a patient's local pharmacy team will produce more vaccinations than otherwise identical messages.


Eligibility criteria:
exclusion criteria: 1. the patient unsubscribed from texts before the send date and time of the patient's sms/mms message 2. the patient received a bivalent covid booster before the send date and time of the patient's sms/mms message.

Keywords: covid-19 behavioral science interventions vaccination promotion
remote rehabilitation via the internet in patients after a stroke - physical rehabilitation using biofeedback systems to improve upper extremity function

Conditions: Stroke Patients

Summary: the objective of this study is to examine monitored rehabilitation therapy over the internet to improve upper limb function for stroke patients. home rehabilitation for stroke patients will avoid the burden of arrival to the health facilities, making it easier on them and improve their quality of life and the lives of their caregivers. to achieve this goal the investigators will examine the effectiveness and feasibility of home rehabilitation system of upper limb, consisting of ergonomic accessories (hand and arm tutors). the quantitative indices will be based on the quantitative clinical measures that are used in regular evaluations of stroke patients and function and range of motion indices as received from the system.


Eligibility criteria:
inclusion criteria: * stroke patients who had at least eight conventional rehabilitation treatments lasted at least until a month before the start of the experiment, * not affected cognitively (to be determined by the score on the mini mental exam greater than 23). * patients have daily access to a computer and the internet, and use a personal caregiver or family member can supervise the use of the system. exclusion criteria: * global or sensory aphasia, unilateral spatial neglect, apraxia and other acute neurological or orthopedic conditions.
use of long-acting injectable cabotegravir/rilpivirine for the treatment of hiv in belgium

Conditions: Human Immunodeficiency Virus

Summary: this will be a multi-center, single arm observational cohort study with an assessment of patient-reported outcomes (pros) and of clinical and virologic outcomes. primary outcome • evaluate patient perception of, and satisfaction with, long-acting injectable (lai) cabotegravir/rilpivirine (cab/rpv) for the treatment of hiv secondary outcomes • description of the demographic, hiv-, and non-hiv-related characteristics of participants included in this analysis


Eligibility criteria:
inclusion criteria: * hiv-1 patients, aged 18 years and above, having received at least 1 dose of lai cab/rpv between september 1, 2021, and march 31, 2024.
safety study of snx-5422 to treat solid tumor cancers and lymphomas

Conditions: Solid Tumor Malignancy; Lymphoid Malignancy (Lymphoma and CLL); Leukemia; Lymphoma

Summary: hsp90 is a chemical in the body that is involved in promotion of cancer. snx-5422 is an experimental drug that blocks hsp90. it is being evaluated for safety and efficacy in patients with cancer.


Eligibility criteria:
inclusion criteria: * solid tumors or lymphoid malignancies refractory to standard therapy * measurable disease * recovery to grade \< 1 toxicity due to prior adverse event or chemotherapy * no chemotherapy within 4 weeks of entering study * age \> 18 years * karnofsy \>= 60% * life expectancy \> 3 months * normal or adequate organ and marrow function exclusion criteria: * receiving other investigational agents * brain metastases * uncontrolled medical illness * hiv+ receiving combination antiretroviral therapy * significant gi disease
second-line irinotecan vs. ilf for agc

Conditions: Stomach Neoplasm; Metastatic; Second-Line

Summary: patients with recurrent or metastatic gastric cancer can benefit from palliative chemotherapy. however, over half of patients with metastatic gastric cancer who received chemotherapy failed to achieve response and even in these responders, the duration of responses was as short as a few months. patients with metastatic gastric cancer who fail to respond or have relapse after first line chemotherapy have a grim prognosis and a standard salvage treatment is not available. we designed this phase ii trial to determine the efficacy and safety of irinotecan monotherapy or combination (ilf) as second-line therapy for advanced gastric cancer.


Eligibility criteria:
inclusion criteria: * histologically confirmed gastric cancer * inoperable, recurrent, or metastatic * performance status 0 to 2 * failed after one or more prior chemotherapy for advanced disease * informed consent exclusion criteria: * active infection * severe co-morbidities * previously treated with irinotecan or similar drugs
china early esophageal cancer cohort

Conditions: Early Esophageal Cancer

Summary: with the development of endoscopy, more and more patients with superficial esophageal squamous cell carcinoma (escc) receive endoscopic resection rather than traditional surgery. however, there is still no complete consensus on the risk factors for lymph node metastasis (lnm) and recurrence of escc after endoscopic resection. the existing curative resection criteria are strict to a certain extent, and a considerable number of patients are overtreated according to the current standard of additional treatment. thus, we aim to conduct a multi-center retrospective and prospective study to construct a large cohort of escc based on the previously established multi-center collaborative research network and clinical big data, analyze the risk factors of lnm and recurrence in patients with early esophageal squamous cell carcinoma after esd, establish an accurate and simple risk prediction model, and evaluate the discrimination efficiency of this model.


Eligibility criteria:
inclusion criteria: 1. men and women, aged 18-85. 2. esd was performed for early (superficial) esophageal squamous cell carcinoma, and the indication was in line with domestic and foreign guidelines. 3. the pathological stage after esd was pt1a/pt1b. 4. the effective follow-up time after esd was ≥3 years, or recurrence or lnm occurred during the follow-up period. exclusion criteria: 1. esophageal chemoradiotherapy or esophageal surgery were performed before esd. 2. there is a history of carcinoma, early carcinoma, adenoma and other benign and malignant tumors of stomach and duodenum. 3. pathological data after esd were incomplete. 4. combined with malignant tumors of other organs. 5. fragmented endoscopic mucosal resection (emr), multi-loop mucosal resection (mbm) and other endoscopic non-monolithic resection techniques were used. 6. new squamous cell carcinoma in other parts of esophagus during follow-up (metachronous carcinoma).